Mass spectrometry complements bone marrow minimal residual disease assessment
The position of MS regarding detection of MRD in the BM is one important question. MRD data were not systematically collected within the GMMG-MM5 trial. However, for 45 patients BM MRD (sensitivity 1 × 10